Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Diazoxide-resistant diffuse hyperinsulism (DRDH) is a form of Diazoxide resistant hyperinsulinism characterized by recurrent episodes of profound hypoglycemia caused by an excessive/ uncontrolled insulin secretion (inappropriate for the level of glycemia) due to diffuse involvement of pancreas that is unresponsive to medical treatment with diazoxide, often necessitating near total/total pancreatectomy.
No clinical trials have been registered for diazoxide-resistant diffuse hyperinsulinism.
1 publication has been identified in PubMed for diazoxide-resistant diffuse hyperinsulinism. Research spans Case Report / Case Series (100%).
Telehuz D (2024). [PMID: 38952388](https://pubmed.ncbi.nlm.nih.gov/38952388/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center